PureTech Health PLC PRTC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PRTC is a good fit for your portfolio.
News
-
PureTech Announces Annual Results for Year Ended December 31, 2023
-
PureTech Health: Notice of Results
-
PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis
-
PureTech Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers
-
PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions
-
PureTech Proposes $100 Million Capital Return
-
Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion
-
PureTech Receives Orphan Drug Designation for LYT-200 in Acute Myeloid Leukemia
Trading Information
- Previous Close Price
- GBX 212.50
- Day Range
- GBX 207.00–219.50
- 52-Week Range
- GBX 139.00–242.93
- Bid/Ask
- GBX 0.00 / GBX 0.00
- Market Cap
- GBX 58.85 Bil
- Volume/Avg
- 865,590 / 528,564
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 998.46
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 2.69%
Company Profile
PureTech Health PLC is a biopharma company developing medicines to modulate the adaptive human system. It is a cross-disciplinary healthcare company developing products that could improve the lives of patients. The company is focused on developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic, and immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological & neuropsychological disorders, among others. It operates in the following segments: Internal, Controlled Founded Entities, Non-Controlled Founded Entities, and Parent Companies & Others. The company has a robust pipeline of advanced programs that are post-human proof of concept and focused on some of society's healthcare needs.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 90
- Website
- https://www.puretechhealth.com
Comparables
Valuation
|
Metric
|
PRTC
|
RYTM
|
QURE
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.63 | 13.90 | 1.05 |
Price/Sales | 998.46 | 29.58 | 13.72 |
Price/Cash Flow | — | — | — |
Price/Earnings
PRTC
RYTM
QURE
Financial Strength
|
Metric
|
PRTC
|
RYTM
|
QURE
|
|---|---|---|---|
Quick Ratio | 6.64 | 5.27 | 8.44 |
Current Ratio | 6.76 | 5.58 | 8.85 |
Interest Coverage | −2.86 | −13.26 | −6.85 |
Quick Ratio
PRTC
RYTM
QURE
Profitability
|
Metric
|
PRTC
|
RYTM
|
QURE
|
|---|---|---|---|
Return on Assets (Normalized) | −21.43% | −46.12% | −35.54% |
Return on Equity (Normalized) | −29.05% | −76.97% | −82.34% |
Return on Invested Capital (Normalized) | −27.92% | −76.40% | −55.12% |
Return on Assets
PRTC
RYTM
QURE
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Nyjbqgvbr | Fhly | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Tlhlkpng | Jttqq | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Crwzpjk | Wlzyk | $97.8 Bil | |
MRNA
| Moderna Inc | Nfgpzxxxp | Hchx | $41.3 Bil | |
ARGX
| argenx SE ADR | Vfvfhss | Pwhk | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Ypyxbydpk | Wnv | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Wdttqsf | Tvwsnk | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Jypqcdz | Gfwrlfk | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Czrqkxzm | Xpdmtm | $12.5 Bil | |
INCY
| Incyte Corp | Pltgwjcb | Xgwszjk | $11.6 Bil |